The estimated Net Worth of Plew Daniel P Van is at least $60.4 Million dollars as of 14 February 2024. Mr. Van owns over 10,434 units of Regeneron Pharmaceuticals stock worth over $23,260,468 and over the last 17 years he sold REGN stock worth over $29,310,340. In addition, he makes $7,829,510 as Executive Vice President and General Manager - Industrial Operations and Product Supply at Regeneron Pharmaceuticals.
Daniel has made over 34 trades of the Regeneron Pharmaceuticals stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 10,434 units of REGN stock worth $9,831,750 on 14 February 2024.
The largest trade he's ever made was exercising 85,579 units of Regeneron Pharmaceuticals stock on 6 May 2020 worth over $4,452,675. On average, Daniel trades about 16,665 units every 91 days since 2007. As of 14 February 2024 he still owns at least 20,378 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Van stock trades at the bottom of the page.
Daniel P. Van Plew serves as Executive Vice President, General Manager - Industrial Operations and Product Supply of the Company since January 2016. From April 2008 to December 2015, Mr. Van Plew served as Senior Vice President and General Manager, Industrial Operations and Product Supply. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in 2007. From 2006 until 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his M.S. in Chemistry from The Pennsylvania State University and his M.B.A. from Michigan State University.
As the Executive Vice President and General Manager - Industrial Operations and Product Supply of Regeneron Pharmaceuticals, the total compensation of Daniel Plew at Regeneron Pharmaceuticals is $7,829,510. There are 7 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Daniel Plew is 47, he's been the Executive Vice President and General Manager - Industrial Operations and Product Supply of Regeneron Pharmaceuticals since 2016. There are 24 older and no younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: